Santhera Deal History & Licensing Activity
Santhera is a biotech. Over the past three years, Santhera has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (5 deals). The company currently has 2 active clinical trials, primarily in Rare Disease.
Deals (12mo)
2
Active Trials
2
Top Modality
Small Molecules
Focus Area
Rare Disease
Santhera Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Santhera in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| AGAMREE (vamorolone) | Biomedica | Small Molecules | Approved | license | Jul 13, 2026 |
| vamorolone | Nxera Pharma | Small Molecules | Approved | license | Jan 8, 2026 |
Santhera Pipeline Focus
Therapeutic areas and modalities where Santhera is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Santhera Clinical Pipeline
Santhera has 2 active clinical trials across 2 development phases.
1
Phase 4
1
Unknown
See How Your Asset Matches Santhera's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Santhera Licensing & Deal Activity
Santhera is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Santhera ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Santhera include Rare Disease (5 deals and trials), and Rare Disease (2 deals and trials). In terms of modality, Santhera has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Santhera and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Santhera's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.